Radiolabeled Nanoparticles for Diagnosis and Therapy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".
Deadline for manuscript submissions: closed (20 June 2023) | Viewed by 2335
Special Issue Editor
Interests: nanomedicine; nuclear medicine; vectorized internal therapy; photodynamic therapy; Cerenkov radiations
Special Issue Information
Dear Colleagues,
Because the world’s population is continuously growing while life span increases, cancer is expected to be the main cause of death in the world in the 21st century. Therefore, the development of diagnostic and therapeutic strategies for the management of cancer is of high importance.
The use of nanoparticles in cancer diagnosis and therapy has continuously increased for the last decade. Most applications of such systems were dedicated to radiosensitization purposes in the external radiotherapy context. However, external radiotherapy can induce unwanted damages to healthy tissues. Moreover, extracellular matrix degradation through ionizations is responsible for tumoral cells’ migration. In this context, internal radiotherapy appears as a promising strategy. Conjoint use of nanoparticles and radioelements can then be used for both diagnosis and therapy, depending on the type of emission allowed by the chosen isotope.
The range of applications and methods allowed by such association is wide, from positron emission tomography (PET) imaging, with very specific radiotracers, to deep-seated photodynamic therapy and, of course, brachytherapy. The next step toward a true personalized medicine strategy will be the use of the same nanoplatform to label two different isotopes: the first for diagnosis and prognosis and the second for the therapy. In this way, we can predict if the treatment will reach the tumor site specifically and then predict its efficacy before initiating it.
In this Special Issue, we welcome submissions of high-quality research and review articles presenting investigations of involving nanoparticles and nuclear medicine for both diagnosis and therapy. We welcome all types of reports, including in silico, in vitro, and in vivo studies, but also more interdisciplinary papers presenting physical and numerical models as well as the dosimetry of investigated methods.
Dr. Joël Daouk
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vectorized internal radiotherapy
- brachytherapy
- functional imaging
- Cerenkov imaging
- photodynamic therapy
